Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).